Search Results
Your search for ,OUr matches 10645 pages
Showing 2101 - 2150Cost-Effectiveness of Chemotherapy Sequences in Metastatic Breast Cancer According to Prior Therapy Exposure
In a modeling study reported in the Journal of Clinical Oncology, Stephanie B. Wheeler, PhD, MPH, and colleagues identified the most cost-effective sequences of single-agent chemotherapy regimens among patients with endocrine-refractory or triple-negative metastatic breast cancer according to prior ...
Sequencing of Ipilimumab/Nivolumab With Encorafenib/Binimetinib in BRAF-Mutant Metastatic Melanoma
In a phase II trial (SECOMBIT) reported in the Journal of Clinical Oncology, Paolo A. Ascierto, MD, and colleagues found that sequential immunotherapy and targeted therapy with ipilimumab/nivolumab followed at disease progression by encorafenib/binimetinib was associated with good survival...
Expert Point of View: Jacek Jassem, MD
Abstract discussant, Jacek Jassem, MD, of the Medical University of Gdansk, in Poland, underscored smoking as the most important cause of lung cancer, noting that between 85% and 90% of patients with lung cancer are current or former smokers. “Lung cancer screening, which has recently become...
Updated Overall Survival Findings With Adjuvant Erlotinib vs Vinorelbine/Cisplatin in EGFR-Mutant Stage IIIA NSCLC
As reported in the Journal of Clinical Oncology by Yue et al, an updated analysis of the Chinese phase II EVAN study indicated a sizable overall survival advantage with adjuvant erlotinib vs vinorelbine/cisplatin in patients with R0 resected stage IIIA EGFR-mutant non–small cell lung cancer...
Dual Checkpoint Inhibitor Blockade as First-Line or Salvage Therapy for Patients With Advanced Merkel Cell Carcinoma
Merkel cell carcinoma has a high rate of metastasis and poor patient outcomes. The current standard of care for patients with recurrent, unresectable, or metastatic disease is immune checkpoint inhibitor monotherapy targeting PD-1 and PD-L1, but only about half of patients respond to this therapy....
Early Research Identifies Effective Combination Immunotherapy for Subgroup of Patients With Metastatic Colorectal Cancer
A physician-scientist at City of Hope has identified a novel combination immunotherapy regimen—a triplet therapy consisting of regorafenib, ipilimumab, and nivolumab—that demonstrated significant response in patients with chemotherapy-resistant, microsatellite-stable metastatic colorectal cancer....
ASCO Applauds President Biden’s Leadership in Relaunching the Cancer Moonshot
On September 12, Lori J. Pierce, MD, FASTRO, FASCO, Board Chair of the Association for Clinical Oncology (ASCO), made the following statement: “President John F. Kennedy’s historic speech that inspired our nation and an entire generation of Americans to achieve manned space exploration underscored ...
Neoadjuvant Cemiplimab in Patients With Stage II to IV Cutaneous Squamous Cell Carcinoma
In an international, multicenter phase II clinical trial, 63.3% of patients with stage II to IV cutaneous squamous cell carcinoma saw their tumors nearly or completely eradicated when treated with the anti–PD-1 agent cemiplimab-rwlc before surgery. The results were presented by Gross et al at the...
SWOG S1801: Neoadjuvant and Adjuvant Pembrolizumab for Patients With Stage IIIB to IV Melanoma
Patients with high-risk melanoma who received the anti–PD-1 therapy pembrolizumab both before and after surgery to remove cancerous tissue had a significantly lower risk of their cancer recurring than similar patients who received the drug only after surgery. These results from a study by the SWOG...
Researchers Examine How Air Pollution May Drive Lung Cancer in Never-Smokers
A new mechanism has been identified through which very small pollutant particles in the air may trigger lung cancer in people who have never smoked, paving the way to new prevention approaches and the development of novel therapies, according to late-breaking data reported by Charles Swanton, MBBS, ...
ESMO and EONS Announce Launch of PrEvCan
On September 9, the European Society for Medical Oncology (ESMO), together with the European Oncology Nursing Society (EONS), announced the launch of the Europe-wide “Cancer Prevention Across Europe” campaign (PrEvCan) aimed at reducing the burden of cancer. The announcement was made at the opening ...
An Aggressive Type of Non-Hodgkin Lymphoma Threatened My Life
I was just 31 and about to give birth to my fourth child, Yitzchok, when I received a diagnosis of primary mediastinal large B-cell lymphoma. The news was terrifying and crippling. For months, I had been experiencing shortness of breath, coughing, and a pain in my left shoulder, all of which were...
How EQRx Aims to Reengineer the Health-Care System to Produce More Effective, Less Costly Cancer Drugs
The numbers are dizzying. The costs of cancer care in the United States are rising so fast that by 2030, it is projected the national cancer-attributable costs will total more than $246 billion, up from $183 billion in 2015—a 34% increase.1 And although the total global economic burden of cancer is ...
Study Shows 2 Million Life-Years Lost and $21 Billion in Lost Earnings Annually From Smoking-Associated Cancer
A recent study led by researchers at the American Cancer Society (ACS) reported that nearly 123,000 cancer deaths, or close to 30% of all cancer deaths, were from cigarette smoking in the United States in 2019, leading to more than 2 million person-years of lost life and nearly $21 billion in...
Association of Community Cancer Centers Announces 2022 Innovator Award Winner, Ochsner Cancer Institute
The Association of Community Cancer Centers (ACCC) recently announced that Ochsner Cancer Institute in New Orleans is a recipient of a 2022 ACCC Innovator Award. The award recognizes Ochsner Cancer Institute’s Chemotherapy Care Companion program—a digital technology system that allows the cancer...
Neurosurgeon Ashish Shah, MD, Returns to Sylvester to Head Clinical Trials and Translational Research on Brain Tumors
Ashish Shah, MD, has assumed the newly created position of Director of Clinical Trials and Translational Research and principal investigator in the Section of Virology and Immunotherapy at Sylvester Comprehensive Cancer Center’s Brain Tumor Initiative (BTI) at the University of Miami Miller School ...
ASCO Updated Guideline of Biomarkers in Metastatic Breast Cancer Supports PIK3CA, BRCA1/2, PD-L1 Testing
ASCO has issued a new practice guideline update on the use of biomarkers in the management of metastatic breast cancer.1 The updated guideline revisits recommendations from the 2015 guideline and addresses topics that have emerged since then in the move toward personalized medicine in metastatic...
Thomas J. Herzog, MD, to Serve as Board President-Elect of the GOG Foundation, Inc, for Gynecologic Malignancies
The GOG Foundation, Inc (GOG-F), Board of Directors recently announced the election of Thomas J. Herzog, MD, as its next President, succeeding Larry J. Copeland, MD, who has served in this role since 2017. Under Dr. Copeland’s leadership, the GOG-F has experienced unprecedented growth in its...
Report Finds Cancers in Adults Younger Than Age 50 Are on the Rise Globally
Over recent decades, more and more adults under the age of 50 are developing cancer. A recently published study revealed that the incidence of early-onset cancers (those diagnosed before age 50)—including breast, colon, esophageal, kidney, liver, and pancreatic cancers, among others—has...
Wall Street Doesn’t Believe in This Target
March 2, 2009. Just published in the Journal of Clinical Investigation.1 And we even got the cover. Twists and turns of heat shock protein-90 (Hsp90), the chaperone, the evolutionary capacitor. Great name and important cancer target. People smiled when I talked about this at the Hsp90 conference....
V. Craig Jordan, CMG, OBE, PhD, DSc, FMedSci, the ‘Father of Tamoxifen,’ Recounts a Life of Adventure and Science
In 2019, Her Majesty Queen Elizabeth II appointed V. Craig Jordan, CMG, OBE, PhD, DSc, FMedSci, Companion of the Most Distinguished order of St. Michael and St. George (CMG), honoring his extraordinary scientific work in the development of selective estrogen receptor modulators, most notably...
Concurrent Chemoradiation Therapy With Weekly Cisplatin for Locally Advanced Head and Neck Squamous Cell Carcinoma
When combined with radiotherapy as definitive treatment of locally advanced head and neck squamous cell carcinoma, cisplatin at a dose of 40 mg/m2 weekly is noninferior to cisplatin at 100 mg/m2 every 3 weeks, according to the results of the ConCERT trial.1 These findings were presented by Atul...
Final Analysis of GRIFFIN Study Presented for Daratumumab-Based Investigational Quadruplet Regimen in Newly Diagnosed, Transplant-Eligible Patients With Multiple Myeloma
The randomized phase II GRIFFIN study evaluated the investigational use of daratumumab in combination with lenalidomide, bortezomib, and dexamethasone (RVd), followed by maintenance therapy with daratumumab and lenalidomide, compared to RVd followed by maintenance therapy with lenalidomide alone,...
Report Finds 'Batwing' Mastopexy May Enable More Women to Undergo Nipple-Sparing Mastectomy
Nipple-sparing techniques can provide better outcomes for women undergoing breast reconstruction after mastectomy, but due to complication risks, these approaches are often not offered to women with sagging or larger breasts. For this group of patients, a “batwing” incision may provide a safer...
Two New Studies Find Aggressive Prostate Cancer May Be Linked to Ancestral Heritage
Two studies published simultaneously by Jaratlerdsiri et al in Nature and Gong et al in Genome Medicine have identified genetic signatures explaining ethnic differences in the severity of prostate cancer, particularly in sub-Saharan Africa. Through genetic sequencing of prostate cancer tumors from...
Can Patients With Low-Risk Nasopharyngeal Cancer Be Treated Safely With Radiotherapy Alone?
Intensity-modulated radiation therapy (IMRT) alone may be considered an effective treatment option for “low-risk” T1–2N1 and T3N0 nasopharyngeal carcinoma, according to trial data presented by Jun Ma, MD, MS, Professor of Radiation Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China,...
Cabozantinib Prolongs Progression-Free Survival in Previously Treated Radioiodine-Refractory Differentiated Thyroid Cancer
As reported in The Lancet Oncology by Marcia S. Brose, MD, Abramson Cancer Center, University of Pennsylvania, and colleagues, the phase III COSMIC-311 trial has shown that cabozantinib produced a numerically higher objective response rate and significantly prolonged progression-free survival vs...
Study Finds AI Ultrasound Platform Can Predict Thyroid Malignancy, Pathologic Stage, and BRAF Mutation Status
An artificial intelligence (AI) ultrasound platform that incorporates multiple methods of machine learning can accurately predict thyroid malignancy as well as pathologic and genomic outcomes, according to data presented at the 2022 Multidisciplinary Head and Neck Cancers Symposium.1 Findings from...
De-escalation of Radiation Therapy for HPV-Positive, Intermediate-Risk Oropharyngeal Cancer
De-escalated adjuvant radiotherapy appears to be safe in patients with surgically resectable, human papillomavirus (HPV)--positive oropharyngeal cancers, particularly in patients without extranodal extension or pN2 disease by American Joint Committee on Cancer (AJCC) 8th edition. These findings...
Midtreatment Imaging De-escalates Therapy for Half of Study Patients With Oropharyngeal Cancer
Positron-emission tomography (PET) scans obtained before and midway through treatment may be used to de-escalate therapy for patients with oropharyngeal cancer, leading to fewer side effects, according to data presented at the 2022 Multidisciplinary Head and Neck Cancers Symposium.1 An interim...
Are Disadvantaged Patients Less Likely to Receive Advanced Radiotherapy Techniques for Head and Neck Cancer?
Advanced radiotherapy techniques may reduce the risk of severe and debilitating toxicity associated with radiation, but not all patients have equal access to these modalities, according to data presented at the 2022 Multidisciplinary Head and Neck Cancers Symposium.1 Retrospective analysis of the...
Head and Neck Cancer 2021–2022 Almanac
Head and neck cancer is the seventh most common cancer in the world, with 1.1 million new diagnoses reported annually.1 In the United States, the incidence of oral and pharyngeal cancers is over 54,000 cases per year, resulting in over 11,000 yearly deaths.2 Although smoking and alcohol consumption ...
Researchers Outline a Path to Representation in Cancer Clinical Trials
A new study published by Birhiray et al in Blood Advances outlines practical strategies for promoting diversity, equity, inclusion, and access in cancer clinical research. The study highlights significant racial disparities in cancer research, citing that between 2008 and 2018, only 7.8% of...
Deep-Learning Algorithm May Streamline Lung Cancer Radiotherapy Treatment
Lung cancer, the most common cancer worldwide, is targeted with radiation therapy in nearly one-half of cases. Radiation therapy planning is a manual, resource-intensive process that can take days to weeks to complete, and even highly trained physicians vary in their determinations of how much...
Researchers Identify Markers of Chemotherapy Resistance and Outcome in Patients With Triple-Negative Breast Cancer
Researchers have identified biological markers in patients with triple-negative breast cancer that are associated with resistance to chemotherapy. The study was published by Anurag et al in the journal Cancer Discovery and was funded by the National Cancer Institute’s Clinical Proteomics Tumor...
Clinical and Translational Researcher Rossana Berardi, MD, Works to Overcome the Gender Gap in Oncology in Italy
In our continuing effort to connect and learn more about our international oncology colleagues, The ASCO Post recently spoke with Rossana Berardi, MD, Professor in Medical Oncology and Director of the Postgraduate School of Oncology at the Università Politecnica Marche, Ancona, Italy, where she is...
International Career Joins Cancer Research and Clinical Care of Patients With Lung Cancer
Pilar Garrido, MD, PhD, is Head of the Medical Oncology Department, University Hospital Ramón y Cajal, Madrid. She is also Co-Director of the Cancer Research Group at Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS). Her main areas of research and clinical interest are thoracic tumors,...
MRI-Guided Ultrasound Focal Therapy May Delay or Avoid Prostatectomy or Radiotherapy in Patients With Intermediate-Risk Prostate Cancer
MRI-guided focused ultrasound focal therapy produced “a high degree of success” and “a low rate of genitourinary adverse events” when used to treat select patients with intermediate-grade prostate cancer, Behfar Ehdaie, MD, MPH, and colleagues reported in The Lancet Oncology.1 Dr. Ehdaie is...
An Oncologist and His Patient With Cancer Look at the Intimate Experience of Life and Death
"This e-mail is different from my usual. No smiley faces or funny cartoons, for I have moved on to another location…. My place in the long line of life has suddenly been jumped up to the head of the queue, and now I have a boarding pass,” notes Harry, a patient with end-stage lung cancer who has...
Long-Term Benefit of Radiotherapy Confirmed in Advanced Prostate Cancer: STAMPEDE Trial Follow-up
Radiotherapy to the prostate in addition to standard treatment may improve survival for some men with advanced prostate cancer without detriment to quality of life, long-term study results from the STAMPEDE trial confirmed. These findings were published by Chris C. Parker, MD, and colleagues in...
How Did the First Year of the COVID-19 Pandemic Affect Cancer Survivors?
Recent research published by Xuesong Han, PhD, and colleagues in the journal Cancer indicated that during the first year of the COVID-19 pandemic, the proportion of working-aged U.S. adults without health insurance did not change despite increases in unemployment. The prevalence of unhealthy...
Study Examines Effects of Advance Care Planning for Adolescents With Cancer
In a recently published study by Needle et al in JAMA Network Open, University of Minnesota researchers and colleagues say adolescents with cancer deserve a voice in medical decisions made for and about them. “Adolescents with cancer should be given the opportunity to participate in their own...
Proximity to Fracking Sites May Be Associated With Risk of Pediatric Leukemia
Children in Pennsylvania living near unconventional oil and gas developments at birth were two to three times more likely to be diagnosed with leukemia between the ages of 2 and 7 years than children who did not live near this oil and gas activity, after accounting for other factors that could...
Cancer-Related Fatigue Linked to Balance Problems After Chemotherapy for Breast Cancer
For many patients who have received chemotherapy for breast cancer, cancer-related fatigue is a persistent side effect—and one that contributes to ongoing balance problems, suggests a recent paper published by Weschler et al in Rehabilitation Oncology. The new research by Stephen Wechsler, PT, DPT, ...
Rituximab, Lenalidomide, and Ibrutinib With Sequential Addition of Chemotherapy in Newly Diagnosed DLBCL: Smart Start Trial
In a single-institution phase II trial (Smart Start) reported in the Journal of Clinical Oncology, Jason Westin, MD, MS, and colleagues found that initiating treatment with rituximab, lenalidomide, and ibrutinib (RLI) followed by the sequential addition of chemotherapy resulted in high response...
Nine Oncology Practices Certified Through ASCO Patient-Centered Cancer Care Certification Pilot
ASCO recently announced that nine outpatient oncology group practices have achieved certification through the new ASCO Patient-Centered Cancer Care Certification pilot based on their adherence to oncology medical home (OMH) standards, a single set of comprehensive, expert-backed standards for...
New Guideline Updates Address Stage IV Non–Small Cell Lung Cancer With and Without Driver Alterations
Two ASCO guideline updates provide new evidence-based recommendations for the systemic treatment of stage IV non–small cell lung cancer (NSCLC) with and without driver alterations.1,2 Among several other updates, these new guidelines add the ALK and ROS1 inhibitor lorlatinib and the PD-L1 immune...
Anthony S. Fauci, MD, to Step Down From Current Roles in December
Anthony S. Fauci, MD, Director of the National Institute of Allergy and Infectious Diseases (NIAID), announced his intention to step down from his various roles in December 2022. He issued the following statement on August 22: I am announcing today that I will be stepping down from the positions...
APHINITY Trial in Patients With HER2-Positive Early Breast Cancer: Update at 8 Years
Updated results from the adjuvant APHINITY trial in HER2-positive early breast cancer, now with a median follow-up of 8.4 years, confirmed the benefit of adding pertuzumab to trastuzumab plus chemotherapy in preventing invasive disease recurrences, but as yet no statistically significant overall...
Study Evaluates UV Protective Behaviors in American Indian and Alaskan Native Populations
Ultraviolet (UV) protection from the sun and avoiding indoor tanning play important roles in reducing a person’s risk for skin cancer, the most common cancer in the United States and one of the most preventable. A recent article published by Yang et al in the Journal of the American Academy of...
